Safety and Efficacy of Intravenous Tigecycline in Subjects with Secondary Bacteremia: Pooled Results from 8 Phase III Clinical Trials

Abstract

Tigecycline was generally safe and well tolerated in the treatment of secondary bacteremia associated with cSSSI, cIAI, and CAP; cure rates were similar to comparative standard therapies.